• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫表型与接受基于替莫唑胺的标准治疗和免疫治疗的胶质母细胞瘤患者的生存相关。

Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.

作者信息

Antonopoulos Markos, VAN Gool Stefaan W, Dionysiou Dimitra, Graf Norbert, Stamatakos Georgios

机构信息

Institute of Communication and Computer Systems, School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece

Immuno-Oncologic Center Köln, Köln, Germany.

出版信息

Anticancer Res. 2019 Apr;39(4):2043-2051. doi: 10.21873/anticanres.13315.

DOI:10.21873/anticanres.13315
PMID:30952748
Abstract

BACKGROUND/AIM: The need for more effective treatment modalities that can improve the clinical outcome of patients with glioblastoma multiforme remains imperative. Dendritic cell vaccination is a fast-developing treatment modality, currently under exploration. Functional immune cell subpopulations may play a role in the final outcome.

MATERIALS AND METHODS

Data from 101 patients drawn from the HGG-2010 trial, including baseline patient characteristics and fluorescence-activated cell sorting of immune cell subpopulations, were analyzed by statistical and machine-learning methods.

RESULTS

The analysis revealed strong correlations between immune profiles and overall survival, when the extent of resection and the vaccination schedule were used as stratification variables.

CONCLUSION

A systematic, in silico workflow detecting strong and statistically significant correlations between overall survival and immune profile-derived quantities obtained at the start of dendritic cell vaccination was devised. The derived correlations could serve as a basis for the identification of prognostic markers discriminating between potential long- and short-term survivors of patients with glioblastoma multiforme.

摘要

背景/目的:对于多形性胶质母细胞瘤患者,仍迫切需要能改善临床结局的更有效治疗方式。树突状细胞疫苗接种是一种快速发展的治疗方式,目前正在探索中。功能性免疫细胞亚群可能在最终结局中发挥作用。

材料与方法

对来自HGG - 2010试验的101例患者的数据进行分析,包括患者基线特征以及免疫细胞亚群的荧光激活细胞分选,采用统计和机器学习方法。

结果

当将切除范围和疫苗接种方案用作分层变量时,分析显示免疫特征与总生存期之间存在强相关性。

结论

设计了一种系统性的计算机模拟工作流程,用于检测树突状细胞疫苗接种开始时获得的总生存期与免疫特征衍生量之间的强且具有统计学意义的相关性。所衍生的相关性可为识别多形性胶质母细胞瘤患者潜在长期和短期幸存者的预后标志物提供依据。

相似文献

1
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.免疫表型与接受基于替莫唑胺的标准治疗和免疫治疗的胶质母细胞瘤患者的生存相关。
Anticancer Res. 2019 Apr;39(4):2043-2051. doi: 10.21873/anticanres.13315.
2
A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.一项针对新诊断的胶质母细胞瘤患者,在荧光引导手术之后进行自体树突状细胞疫苗接种和放化疗的II期试验。
J Transl Med. 2017 May 12;15(1):104. doi: 10.1186/s12967-017-1202-z.
3
Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.自体树突状细胞瘤内免疫治疗在新诊断多形性胶质母细胞瘤患者一线治疗中的整合:一项初步研究。
J Neurooncol. 2010 Sep;99(2):261-72. doi: 10.1007/s11060-010-0131-y. Epub 2010 Feb 10.
4
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.树突状细胞疫苗联合替莫唑胺再治疗:多形性胶质母细胞瘤复发患者的I期试验结果
J Neurooncol. 2015 Jan;121(2):319-29. doi: 10.1007/s11060-014-1635-7. Epub 2014 Oct 31.
5
A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.一项将负载裂解物的成熟树突状细胞疫苗接种纳入新诊断胶质母细胞瘤标准放化疗的随机对照II期试验(GlioVax):一项随机对照试验的研究方案
Trials. 2018 May 25;19(1):293. doi: 10.1186/s13063-018-2659-7.
6
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.新诊断的多形性胶质母细胞瘤患者在放化疗后接受淋巴结内自体肿瘤裂解物-树突状细胞疫苗接种的免疫反应。
J Immunother. 2011 May;34(4):382-9. doi: 10.1097/CJI.0b013e318215e300.
7
Temozolomide for immunomodulation in the treatment of glioblastoma.替莫唑胺在胶质母细胞瘤免疫调节治疗中的应用。
Neuro Oncol. 2018 Nov 12;20(12):1566-1572. doi: 10.1093/neuonc/noy072.
8
Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.皮下免疫原性自体肿瘤裂解物免疫治疗可提高小鼠脑胶质瘤的存活率。
Sci Rep. 2017 Oct 24;7(1):13902. doi: 10.1038/s41598-017-12584-0.
9
Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma.放疗或替莫唑胺化疗增强抗 CD47 治疗脑胶质母细胞瘤。
Innate Immun. 2020 Feb;26(2):130-137. doi: 10.1177/1753425919876690. Epub 2019 Sep 23.
10
DCVax®-L--developed by Northwest Biotherapeutics.DCVax®-L——由西北生物治疗公司研发。
Hum Vaccin Immunother. 2014;10(11):3139-45. doi: 10.4161/hv.29276.

引用本文的文献

1
The Complexity of Malignant Glioma Treatment.恶性胶质瘤治疗的复杂性
Cancers (Basel). 2025 Mar 4;17(5):879. doi: 10.3390/cancers17050879.
2
Glioblastoma vaccines: past, present, and opportunities.胶质母细胞瘤疫苗:过去、现在和未来的机遇。
EBioMedicine. 2024 Feb;100:104963. doi: 10.1016/j.ebiom.2023.104963. Epub 2024 Jan 5.
3
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?多形性胶质母细胞瘤患者的树突状细胞疫苗接种:是否已达成新的里程碑?
Transl Cancer Res. 2023 Aug 31;12(8):2224-2228. doi: 10.21037/tcr-23-603. Epub 2023 Jul 28.
4
Immunotherapy for Recurrent Glioma-From Bench to Bedside.复发性胶质瘤的免疫治疗——从 bench 到 bedside。 (注:bench 与 bedside 在这里可能有特定专业含义,直译为“从实验台到病床边”,意译为“从基础研究到临床应用” ,但按要求不添加解释,保留原文英文词汇)
Cancers (Basel). 2023 Jun 30;15(13):3421. doi: 10.3390/cancers15133421.
5
Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review.免疫肿瘤治疗对胶质母细胞瘤患者的临床疗效:一项系统综述。
Brain Sci. 2023 Jan 17;13(2):159. doi: 10.3390/brainsci13020159.
6
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience.针对异柠檬酸脱氢酶1(IDH1)野生型胶质母细胞瘤成人患者的个体化多模式免疫疗法:单机构经验
Cancers (Basel). 2023 Feb 13;15(4):1194. doi: 10.3390/cancers15041194.
7
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients.TMZ 与个体化多模式免疫治疗的协同作用,可提高 IDH1 野生型 MGMT 启动子未甲基化 GBM 患者的总生存率。
Genes Immun. 2022 Dec;23(8):255-259. doi: 10.1038/s41435-022-00162-y. Epub 2022 Feb 16.
8
Palliative Radiotherapy of Primary Glioblastoma.原发性脑胶质瘤的姑息性放疗。
In Vivo. 2021 Jan-Feb;35(1):483-487. doi: 10.21873/invivo.12282.
9
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged.针对胶质母细胞瘤的随机对照免疫治疗临床试验面临挑战。
Cancers (Basel). 2020 Dec 24;13(1):32. doi: 10.3390/cancers13010032.
10
LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.长链非编码 RNA MIR155HG 通过与 PTBP1 结合激活 Wnt/β-连环蛋白通路促进脑胶质瘤替莫唑胺耐药
Cell Mol Neurobiol. 2021 Aug;41(6):1271-1284. doi: 10.1007/s10571-020-00898-z. Epub 2020 Jun 11.